Infinium Pharmachem Limited

NSEI:INFINIUM Stock Report

Market Cap: ₹3.8b

Infinium Pharmachem Past Earnings Performance

Past criteria checks 2/6

Infinium Pharmachem has been growing earnings at an average annual rate of 28.6%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 63% per year. Infinium Pharmachem's return on equity is 12.7%, and it has net margins of 6%.

Key information

28.6%

Earnings growth rate

23.6%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate63.0%
Return on equity12.7%
Net Margin6.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Investors Still Aren't Entirely Convinced By Infinium Pharmachem Limited's (NSE:INFINIUM) Earnings Despite 38% Price Jump

Sep 20
Investors Still Aren't Entirely Convinced By Infinium Pharmachem Limited's (NSE:INFINIUM) Earnings Despite 38% Price Jump

Many Still Looking Away From Infinium Pharmachem Limited (NSE:INFINIUM)

Aug 04
Many Still Looking Away From Infinium Pharmachem Limited (NSE:INFINIUM)

Infinium Pharmachem (NSE:INFINIUM) Strong Profits May Be Masking Some Underlying Issues

Jun 12
Infinium Pharmachem (NSE:INFINIUM) Strong Profits May Be Masking Some Underlying Issues

Infinium Pharmachem (NSE:INFINIUM) Strong Profits May Be Masking Some Underlying Issues

Nov 06
Infinium Pharmachem (NSE:INFINIUM) Strong Profits May Be Masking Some Underlying Issues

Revenue & Expenses Breakdown

How Infinium Pharmachem makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NSEI:INFINIUM Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,57195810
30 Jun 241,464104740
31 Mar 241,356113660
31 Dec 231,160107590
30 Sep 23964102560
30 Jun 231,05398570
31 Mar 231,14295580
31 Mar 2299161390
31 Mar 2154827240
31 Mar 2036410210
31 Mar 191814130

Quality Earnings: INFINIUM has high quality earnings.

Growing Profit Margin: INFINIUM's current net profit margins (6%) are lower than last year (10.6%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: INFINIUM's earnings have grown significantly by 28.6% per year over the past 5 years.

Accelerating Growth: INFINIUM's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: INFINIUM had negative earnings growth (-6.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (22.3%).


Return on Equity

High ROE: INFINIUM's Return on Equity (12.7%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 10:14
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Infinium Pharmachem Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.